These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34888856)

  • 1. Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology.
    Huang W; Li J; Liao MZ; Liu SN; Yu J; Jing J; Kotani N; Kamen L; Guelman S; Miles DR
    Clin Pharmacol Ther; 2022 Nov; 112(5):968-981. PubMed ID: 34888856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development.
    Kast J; Nozohouri S; Zhou D; Yago MR; Chen PW; Ahamadi M; Dutta S; Upreti VV
    Clin Transl Sci; 2022 Sep; 15(9):2057-2074. PubMed ID: 35677992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
    Mody H; Ogasawara K; Zhu X; Miles D; Shastri PN; Gokemeijer J; Liao MZ; Kasichayanula S; Yang TY; Chemuturi N; Gupta S; Jawa V; Upreti VV
    Clin Pharmacol Ther; 2023 Sep; 114(3):530-557. PubMed ID: 37393588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Pharmacology Considerations for the "Off-the-Shelf" Allogeneic Cell Therapies.
    Mody H; Sutaria DS; Miles D
    Clin Pharmacol Ther; 2024 Jun; 115(6):1233-1250. PubMed ID: 38501153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic-Pharmacodynamic Modeling Approaches.
    Chaudhury A; Zhu X; Chu L; Goliaei A; June CH; Kearns JD; Stein AM
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S147-S159. PubMed ID: 33205434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.
    Qi T; McGrath K; Ranganathan R; Dotti G; Cao Y
    Adv Drug Deliv Rev; 2022 Sep; 188():114421. PubMed ID: 35809868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective.
    Lin X; Lee S; Sharma P; George B; Scott J
    J Clin Oncol; 2022 Oct; 40(30):3501-3509. PubMed ID: 35613410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
    Thibodeaux SR; Milone MC
    Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
    Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
    MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
    Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
    Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
    Gajra A; Zalenski A; Sannareddy A; Jeune-Smith Y; Kapinos K; Kansagra A
    Pharmaceut Med; 2022 Jun; 36(3):163-171. PubMed ID: 35672571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
    Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
    Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
    Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
    Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.